Wire · opportunities
Roche's Divarasib Beats Approved KRAS Inhibitors in Head-to-Head NSCLC Trial
◆ Sectors
Biotech
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 26 October 2026 · Fusion42 review
Roche’s next-generation KRAS G12C inhibitor divarasib outperformed first-generation inhibitors Lumakras and Krazati in the first direct head-to-head trial for non-small cell lung cancer.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You should closely watch Roche’s divarasib as it resets the standard for KRAS G12C lung cancer treatment and could shift prescribing habits fast. Drug developers in targeted oncology must prep for a tougher efficacy bar and new competition for KRAS mutant therapies.
◆ Coverage
1 source · 25 Oct 2026
◆ Related on Wire
◆ Topics
Biotechkras-inhibitorslung-cancerclinical-trialsoncologytargeted-therapy